Fig. 2.

Differences in fractional shortening (FS), ejection fraction (EF), and E/A ratio in rapamycin (red triangles) vs. placebo (blue circles). x-axis value at baseline; y-axis value at week 11; dotted red lines no change. Rapamycin significantly improved both FS as a measure of systolic function and the E/A ratio as a measure of diastolic function in rapamycin-treated dogs when compared to placebo. Note that FS improvement was more marked in dogs whose baseline scores were low, which is presumably indicative of the existence of a maximum possible FS percentage dictated by cardiac physiology